|Day Low/High||2.17 / 2.47|
|52 Wk Low/High||1.90 / 8.50|
"DOM-INNATE" study opens patient enrollment
Awarded $2M to Advance Preclinical Efficacy Studies
At 12 Months SGX942 Found to be Safe and Well Tolerated with Multiple Potential Ancillary Benefits
Patent describes application of ThermoVax® with RiVax®
Trial Targeted to Begin in Second Quarter of 2017
Highlighted by Revenues of $10.4 Million
Jonathan Moreland, author of InsiderInsights, gives you the lowdown on top stock purchases and sales.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.